Viking Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Vanguard Capital Management has reported beneficial ownership of 5.08% of Viking Therapeutics Inc.'s common stock as of March 31, 2026.
NASDAQ
The Vanguard Group reported a 0% beneficial ownership in Viking Therapeutics Inc. following an internal realignment.
NASDAQ
FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a 5.1% beneficial ownership stake in Viking Therapeutics Inc. as of September 30, 2025.
NASDAQ
FMR LLC and Abigail P. Johnson have reported an 8.7% beneficial ownership stake in Viking Therapeutics Inc. common stock as of June 30, 2025.
NASDAQ
FMR LLC and its affiliates, along with Abigail P. Johnson, have filed an amended Schedule 13G, reporting a beneficial ownership of 10.0% of Viking Therapeutics Inc.'s common stock as of March 31, 2025.
NASDAQ
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 4.5% beneficial ownership stake in Viking Therapeutics, Inc. as of March 31, 2025.
NASDAQ
Investment giant BlackRock, Inc. has reported a 5.3% passive beneficial ownership stake in biotechnology firm Viking Therapeutics, Inc. as of December 31, 2024.